Pfizer in Schizophrenia Deal With Taisho (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japanese drug company Taisho Pharmaceutical has entered negotiations to outlicense an experimental schizophrenia drug to the world's biggest pharmaceutical company, Pfizer. If the deal goes through, Taisho will receive a $22 million upfront payment. Pfizer would then gain development and marketing rights for the drug outside of Japan. Depending on the drug's progress, Taisho could then receive a number of development and milestone payments. (Click here for more
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.